Orphan drugs policy in LATAM

Situation

Lack of knowledge and policies for Orphan Drugs in Latin America

Brix solution

Development and distribution of an informative and educative material about OD. The main objective was to educate health authorities, pharma associations; KOL’s; patient associations and other LATAM stakeholders about the policies in place for OD in US, Europe and Japan. We got some results in very short timing as the recognition from the authorities that OD should be in another scope of analysis. Others took longer because had to evolve to changes in the laws and regulations, but they came with the time. Currently most of Latin America major markets recognize and have OD policies.